The second generation of EORTC-ECIG experimental screening for systemic immunity adjuvants. Its significance for cancer immunotherapy. A comparison of BCG and its hydrosoluble extract.
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D000917:Antibody Formation; D001500:BCG Vaccine; D003601:Cytotoxicity Tests, Immunologic; D005260:Female; D006462:Hemolytic Plaque Technique; D007167:Immunotherapy; D007939:Leukemia L1210 / Q000628:therapy; D008264:Macrophages / Q000276:immunology; D051379:Mice; D009163:Mycobacterium bovis / Q000276:immunology*; D009374:Neoplasms, Experimental / Q000628:therapy*
D000276:Adjuvants, Immunologic; D001500:BCG Vaccine